Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
Gorochov G, Ropers J, Launay O, Dorgham K, da Mata-Jardin O, Lebbah S, Durier C, Bauer R, Radenne A, Desaint C, Vieillard LV, Rekacewicz C, Lachatre M, Parfait B, Batteux F, Hupé P, Ninove L, Lefebvre M, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Botelho-Nevers E, Lelièvre JD, de Lamballerie X, Kieny MP, Tartour E, Paul S. Gorochov G, et al. Among authors: bauer r. JAMA Netw Open. 2024 Apr 1;7(4):e248051. doi: 10.1001/jamanetworkopen.2024.8051. JAMA Netw Open. 2024. PMID: 38652471 Free PMC article.
Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.
Durier C, Ninove L, Lefebvre M, Radenne A, Desaint C, Ropers J, Bauer R, Lebbah S, Carette D, Lachatre M, Lecompte AS, Deplanque D, Botelho-Nevers E, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian J, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Priet S, Levier A, Molino D, Vieillard LV, Parfait B, Lelièvre JD, Tartour E, de Lamballerie X, Launay O; ANRS0002S CoviCompareP Group; AP-HP CoviCompareM Group; Biological resource centers; Laboratories; Trial coordination; Sponsor; Scientific Committee. Durier C, et al. Among authors: bauer r. Sci Rep. 2022 Nov 27;12(1):20373. doi: 10.1038/s41598-022-24409-w. Sci Rep. 2022. PMID: 36437298 Free PMC article.
Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
Durier C, Ninove L, van der Werf S, Lefebvre M, Desaint C, Bauer R, Attia M, Lecompte AS, Lachatre M, Maakaroun-Vermesse Z, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Corbin V, Ansart S, Melica G, Resch M, Netzer E, Kherabi Y, Tardieu R, Lelièvre JD, Tartour E, Meyer L, de Lamballerie X, Launay O; ANRS002S CoviCompareP group. Durier C, et al. Among authors: bauer r. Infect Dis Now. 2024 Mar 16;54(5):104886. doi: 10.1016/j.idnow.2024.104886. Online ahead of print. Infect Dis Now. 2024. PMID: 38494117 Free article.
Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform.
Stuurman AL, Carmona A, Biccler J, Descamps A, Levi M, Baum U, Mira-Iglesias A, Bellino S, Hoang U, de Lusignan S, Bonaiuti R, Lina B, Rizzo C, Nohynek H, Díez-Domingo J; DRIVE Study Contributors. Stuurman AL, et al. Front Public Health. 2023 Jul 20;11:1195409. doi: 10.3389/fpubh.2023.1195409. eCollection 2023. Front Public Health. 2023. PMID: 37546295 Free PMC article.
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Chéret A, Bauer R, Meiffrédy V, Lopez P, Ajana F, Lacombe K, Morlat P, Lascoux C, Reynes J, Calin R, Abel S, Goujard C, Rouzioux C, Avettand-Fenoel V, Meyer L. Chéret A, et al. Among authors: bauer r. J Antimicrob Chemother. 2022 Aug 25;77(9):2506-2515. doi: 10.1093/jac/dkac207. J Antimicrob Chemother. 2022. PMID: 35762503 Clinical Trial.
The build-up of stock of stable integrated proviruses overtime explains the difficulty in reducing HIV-1 DNA levels when treatment is initiated at the chronic stage of the infection.
Mchantaf G, Cheret A, Melard A, Essat A, Gardiennet E, Bauer R, Charre C, Meiffredy V, Piroth L, Goujard C, Meyer L, Avettand-Fenoel V. Mchantaf G, et al. Among authors: bauer r. J Virus Erad. 2023 Dec 9;9(4):100357. doi: 10.1016/j.jve.2023.100357. eCollection 2023 Dec. J Virus Erad. 2023. PMID: 38188640 Free PMC article.
Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis.
Zeggagh J, Bauer R, Delaugerre C, Carette D, Fressard L, Charreau I, Chidiac C, Pialoux G, Tremblay C, Cua E, Robineau O, Raffi F, Capitant C, Spire B, Meyer L, Molina JM; Ipergay Study Group. Zeggagh J, et al. Among authors: bauer r. AIDS. 2022 Jul 1;36(8):1129-1134. doi: 10.1097/QAD.0000000000003187. Epub 2022 Feb 9. AIDS. 2022. PMID: 35142708
HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
Mariaggi AA, Bauer R, Charre C, Gardiennet E, Meiffredy V, Ajana F, Lacombe K, Pialoux G, Cua E, Rouzioux C, Meyer L, Cheret A, Avettand-Fenoel V. Mariaggi AA, et al. Among authors: bauer r. J Antimicrob Chemother. 2022 Feb 23;77(3):735-739. doi: 10.1093/jac/dkab427. J Antimicrob Chemother. 2022. PMID: 35195692
2,448 results